We are a private biopharmaceutical company developing novel antibacterials targeting drug-resistant pathogens that are deemed a critical priority by the WHO.
We develop a novel, safe and efficacious inhibitor of bacterial metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections.
Pseudomonas Elastase Inhibitors (PEi)
A program powered by CARB-X seeking to develop a first-in-class inhibitor of Pseudomonas virulence to be co-administered with standard-of-care antibiotics for the treatment of chronic respiratory infections in Cystic Fibrosis patients.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
